Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

New York Life Investment Management LLC lessened its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 7.4% during the fourth quarter, according to the company in its most ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10 ... estimates have a direct correlation with impending stock price performance. To take advantage of this, we've ...